Request Samples, Vouchers, and/or Coupons
Thank you for your interest in requesting samples, coupons, and/or vouchers. Based on our records, you are not eligible to receive samples, coupons, and/or vouchers. If you have questions, please call our technical support service Monday through Friday between 8 AM and 7 PM ET at 1-800-489-5119. Merck ConnectTM has partnered with Physicians
Actived: 1 days ago
Samples, Vouchers & Coupons
Eligible Health Care Professionals may request available samples, vouchers, and/or coupons for JANUMET® (sitagliptin and metformin HCl) and JANUMET® XR (sitagliptin and metformin HCl extended-release) for use with their appropriate adult patients.
View Patient Resources for JANUVIA® (sitagliptin)
There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management.
Frequently Asked Questions About BRIDION® (sugammadex)
BRIDION works differently than neostigmine by directly encapsulating, binding, and thus inactivating rocuronium or vecuronium. 1-3 After intravenous injection, BRIDION distributes through the plasma and binds to the neuromuscular blocking agents rocuronium or vecuronium to form a complex. 3 BRIDION does not affect the release or breakdown of acetylcholine. 2
Dosing for BRIDION® (sugammadex) Official Site
Drug compatibility. May inject BRIDION into the intravenous line of a running infusion with the following intravenous solutions: 0.9% sodium chloride. 5% dextrose. 0.45% sodium chloride and 2.5% dextrose. Ringer’s solution. Isolyte P with 5% dextrose. Ringer’s lactate …
Patient With Comorbid Condition Patient Profile
BELSOMRA® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Selected Safety Information. BELSOMRA is contraindicated in patients with narcolepsy. BELSOMRA is a central nervous system (CNS) depressant and can impair daytime wakefulness even when used as prescribed.
Discussions for Patients Starting BELSOMRA® (suvorexant) C-IV
Dosing. Important things to discuss with patients starting BELSOMRA Recommend an adequate trial period. The way your patients feel when they fall asleep may be different from their previous experience or expectations 1; It may take a few nights to a week for your patients to assess the effect of BELSOMRA 2,3; In two 3-month clinical trials with BELSOMRA 15 mg and 20 mg, patients reported less
Dosing For BELSOMRA® (suvorexant) C-IV, 5, 10, 15, 20 mg
When used with moderate CYP3A inhibitors, the recommended dosage of BELSOMRA is 5 mg taken no more than once per night (the dose generally should not exceed 10 mg). BELSOMRA is not recommended for use with strong CYP3A inhibitors. Use the lowest dose that is effective for the patient. Patients should take BELSOMRA no more than once per night